v3.23.3
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 1,629,000 $ 846,000 $ 4,892,000 $ 3,525,000
General and administrative 1,354,000 1,315,000 4,727,000 4,255,000
Total operating expenses 2,983,000 2,161,000 9,619,000 7,780,000
Loss from operations (2,983,000) (2,161,000) (9,619,000) (7,780,000)
Other income/(expenses), net:        
Interest and dividend income 43,000 22,000 97,000 43,000
Other income, net 3,000 4,000
Change in fair value of common warrant liability 1,519,000 3,092,000
Transaction costs allocated to common warrant liability (575,000)
Total other income/(expenses), net 1,562,000 25,000 2,614,000 47,000
Net loss (1,421,000) (2,136,000) (7,005,000) (7,733,000)
Other comprehensive loss:        
Unrealized gain on marketable securities 17,000 13,000
Comprehensive loss $ (1,421,000) $ (2,119,000) $ (7,005,000) $ (7,720,000)
Net loss per share, basic $ (0.13) $ (0.24) $ (0.69) $ (0.86)
Net loss per share, diluted $ (0.13) $ (0.24) $ (0.69) $ (0.86)
Weighted-average shares of common stock outstanding, basic 10,693,080 9,067,509 10,154,914 9,039,308
Weighted-average shares of common stock outstanding, diluted 10,693,080 9,067,509 10,154,914 9,039,308

Source